Canagliflozin: A novel treatment option for type 2 diabetes

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1399-1408

  Dietrich, Eric ^a   Powell, Jason ^b   Taylor, James R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Canagliflozin; Oral hypoglycemic; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A9; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE B4;

BODY MASS; DIABETES CONTROL; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSURIA; GLUCURONIDATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INTENTION TO TREAT ANALYSIS; KIDNEY TUBULE ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OSMOTIC DIURESIS; POLLAKISURIA; POLYURIA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

CANAGLIFLOZIN; ORAL HYPOGLYCEMIC; SGLT2 INHIBITOR; TYPE 2 DIABETES;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84888165589     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S48937     Document Type: Review

References (20)

1. American Diabetes Association. Diabetes Statistics. Available from http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed September 14, 2013.
2. Mitka M. More patients get good diabetes control, but only a minority meet all goals. JAMA. 2013;309(13):1335-1336.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al;position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(10): 1364-1379.
4. Chao EC, Henry RR. SGLT2 Inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
5. Wright EM. Renal Na+ glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10-F18.
6. Mackenzie B, Loo DD, Panayotova-Heiermann M, Wright EM. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J Biol Chem. 1996;271(51):32678-32683.
7. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1): 397-404.
8. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125-129.
9. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13: 669-672.
10. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154-2161.
11. INVOKANA® (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc;2013.
12. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.
13. Rosenstock J, Aggarwal N, Polidori D, et al;Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232-1238.
14. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36(9):2508-2515.
15. Devineni, D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6): 539-545.
16. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473.
17. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41(2):72-84.
18. GoodRx [webpage on the Internet]. Available from: http://www.goodRx.com. Accessed September 15, 2013.
19. Neal B, Perkovic V, de Zeeue D, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-a randomized placebo controlled trial. Am Heart J. 2013;166(2);217-223.
20. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158-169.